WINTON GROUP Ltd Sells 4,639 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

WINTON GROUP Ltd trimmed its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 21.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,674 shares of the biotechnology company's stock after selling 4,639 shares during the period. WINTON GROUP Ltd's holdings in BioMarin Pharmaceutical were worth $1,096,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of BMRN. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of BioMarin Pharmaceutical by 13.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 143,145 shares of the biotechnology company's stock worth $9,566,000 after buying an additional 16,471 shares during the last quarter. Korea Investment CORP increased its stake in BioMarin Pharmaceutical by 362.5% in the fourth quarter. Korea Investment CORP now owns 167,903 shares of the biotechnology company's stock valued at $11,036,000 after acquiring an additional 131,600 shares during the last quarter. Prudential Financial Inc. raised its position in BioMarin Pharmaceutical by 131.7% during the fourth quarter. Prudential Financial Inc. now owns 144,082 shares of the biotechnology company's stock valued at $9,426,000 after purchasing an additional 81,887 shares in the last quarter. Vanguard Group Inc. lifted its stake in BioMarin Pharmaceutical by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 19,372,185 shares of the biotechnology company's stock worth $1,273,334,000 after purchasing an additional 93,531 shares during the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth about $4,387,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In related news, CAO Erin Burkhart sold 1,344 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the sale, the chief accounting officer now owns 13,105 shares of the company's stock, valued at $896,119.90. The trade was a 9.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.85% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Piper Sandler raised their price objective on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a report on Thursday, February 20th. UBS Group lifted their price target on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a "buy" rating in a research note on Thursday, February 20th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Finally, Bank of America upped their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of "Moderate Buy" and an average target price of $94.00.

BioMarin Pharmaceutical Stock Up 0.3 %

Shares of BMRN stock traded up $0.24 during midday trading on Wednesday, reaching $68.18. 317,386 shares of the stock were exchanged, compared to its average volume of 1,839,534. BioMarin Pharmaceutical Inc. has a 1 year low of $60.63 and a 1 year high of $94.85. The firm has a market cap of $13.01 billion, a PE ratio of 30.96, a price-to-earnings-growth ratio of 0.61 and a beta of 0.33. The company's 50 day moving average is $67.75 and its two-hundred day moving average is $67.30. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.18. The company had revenue of $747.31 million for the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. On average, equities research analysts predict that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.